Kratom attracts investor interest after WHO decision
- Posted on: 2022-01-13
- Views: 196
By Brody Ford, Bloomberg News
Dec. 20, 2021
(photo by Dimas Ardian/Bloomberg)
Kratom is earning the attention of a biopharma company after the World Health Organization (WHO) decided in early December to reject a “critical review” of the plant.
The WHO panel found in its Dec. 7 decision that it is difficult to link kratom to overdose deaths. Most such deaths also involve other substances.
Atai Life Sciences is known for staging clinical trials of opioid alternatives.
Kratom is a $1.3 billion industry in the U.S.
Shipments of the substance are still seized because of ambiguous laws, including by the U.S. Food and Drug Administration (FDA).
Users of the drug are also so well organized that they’ve been known to send a flood of letters to their representatives in Washington anytime there is movement on the issue.
Kratom advocates say the WHO decision should reduce stigmas and boost business opportunities.
Jenn Lauder, the marketing and advocacy director for Kraken Kratom, one of the largest online kratom companies, said investment interest has surged and a recent industry convention in New York was crawling with venture capitalists.
“I definitely think it opens doors for more companies,” Lauder said. “When people see this is potentially lucrative, that’s always the final push they need.”
Atai is developing a drug derived from kratom to treat pain and opioid-withdrawal symptoms. The company aims to begin clinical trials early next year, according to its chief scientific officer, Srinivas Rao.
Just over 2 million Americans a year consume kratom, with the highest rates occurring among users of opiates, according to a recent New York University study.
Dafna Revah, co-owner of a nearly 50-store retail chain called CBD Kratom, said the WHO panel’s decision should “open doors for customers who were previously hesitant due to the pending assessment.”
The American Kratom Association says growth has been limited by legal ambiguity. In most of the country, it’s sold as a dietary or herbal supplement. Six states have banned it outright, although no new statewide restrictions have occurred since 2016. Five states have passed industry-backed rules dubbed the “Kratom Consumer Protection Act” that include age restrictions and quality standards.
Regulatory concerns keep away most mainstream companies. The FDA’s jurisdiction to seize shipments creates major supply-chain risks since almost all U.S. kratom is imported from Southeast Asian countries like Indonesia and Thailand. Earlier this year, 75,000 pounds of the substance were intercepted and destroyed, and an FDA official said the agency would continue to take action against shipments.
The risks haven’t stopped small companies from exploring the market. LFTD Partners, which largely focuses on cannabis and vaping, is in talks to acquire kratom companies, according to a spokesperson. Kratom-infused gum is being developed by Tauriga Sciences Inc.
As public acceptance grows, Lauder sees kratom following the legalization path set by cannabis — regulations at the state level first and then a push for federal recognition. “In the past five years, we’ve been able to move from being on the defensive to really going on the offense,” she said.